BPC-157 5mg (price is per vial)
$26.32 If paid in BTC $21.06
Total amount of active ingredient: 5mg (1vial)
Availability: In stock
USA : $11.95 (3-5 business days)
International : $49.95 (7-14 business days)
If your shipment was seized (International Orders), we will provide a 50% discount applicable on your next purchase. Please contact us for more information.
Minimum Order: 1vial
Product Usage: THIS PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY.
This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only.
All product information available on this website is for educational purposes only.
Bodily introduction of any kind into humans or animals is strictly forbidden by law.
This product should only be handled by licensed, qualified professionals.
This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.
BPC 157 (Body Protection Compound-157) is a pentadecapeptide made up of 15 amino acids. The amino acids sequence in BPC 157 is similar to a portion of the human BPC amino acid sequence. Human BPC is found in the gastric juice. Experiments have shown that BPC 157 enhances the healing of wounds, including tendons wounds such as transected Achilles tendons of rats. The aim of this study was to investigate the probable mechanism that BPC 157 utilizes to accelerate the healing process in an injured tendon. The study used two groups of tendon explants of which one group was cultured in a BPC 157-containing medium while the other group was cultured in a medium lacking BPC 157. These cultures were thereafter examined for tendon fibroblasts outgrowths. Such outgrowths indicated tendon regeneration. The results revealed that the explants’ outgrowth was significantly accelerated in the culture containing BPC 157 as compared to the culture lacking BPC 157. Also, an MTT assay did show that BPC 157 does not directly affect cellular proliferation in a culture of the rat-derived Achilles tendon. However, results also showed that BPC 157 significantly increased the survival of cells under oxidative stress. Furthermore, the Transwell filter migration assay showed that BPC 157 significantly increased in-vitro fibroblast migration in a dose-dependent fashion. Moreover, BPC 157 accelerated the dispersal of the fibroblasts in culture dishes in a dose-dependent manner.
Additionally, FITC-phalloidin staining was able to demonstrate that BPC 157 induces F-actin formation in fibroblasts. Likewise, Western blot analysis was able to detect the production and activation of paxillin and FAK proteins. The western blot analysis also showed that BPC 157 increases the extent of phosphorylation of paxillin and FAK proteins without affecting the amounts produced.
Thus, it can be concluded that BPC 157 enhances the ex-vivo growth and in-vitro cellular migration of fibroblasts derived from rat tendon explants. Moreover, BPC 157 also increases the probability of a cell surviving under oxidative stress. These actions of BPC 157 are probably mediated by the activation (through phosphorylation) of the proteinic FAK-paxillin pathway.
Molecular Formula: C62H98N16O22
Molecular Weight: 1419.556 g/mol
PubChem CID: 108101
InChI Key: HEEWEZGQMLZMFE-DGQLYNSISA-N
Chemical Names: Bpc 15; Bpc 157; Booly protection compound 15; Bpc-157; BPC-15; UNII-8ED8NXK95P
BPC157 Research Studies
QTc prolongation is a potentially dangerous cardiac condition, which can sometimes result in fatal arrhythmias (erratic and uncontrolled electric signal in the heart). BPC157 BPC 157 was found to reverse QTc prolongation in rats when it was caused by medications including haloperidol, fluphenazine, clozapine, olanzapine, quetiapine, sulpiride, and metoclopramide, all of which are also used in humans. Rats were given weight-appropriate doses of medications, followed by BPC157 doses with EKG recording. QTc prolongation was eliminated rapidly in all test rats and did not occur in them throughout the study. The authors state that BPC157 is suitable for counteracting prolonged QTc interval; this has potential implications for humans who are also at risk of this issue from the same medications.
Bupivacaine is an anesthetic used for many types of surgical procedures, but if accidental overdose occurs it can be very difficult to recover, and may quite rarely result in the death of the patient. Rats were studied with high doses of bupivacaine, injected at 100mg/kg (typical human doses are limited to 175mg, the rat dose is roughly equivalent to a human receiving 10,000mg), and found to have expected cardiac complications. These were largely counteracted by BPC157 administration. Bupivacaine complication was inhibited in BPC157 treated animals, and it should be considered as a potential antidote for bupivacaine cardiotoxicity in humans.
BPC157 was shown to improve alkaline chemical burns in rats. Under anesthesia, rats were exposed to a lye-impregnated piece of filter paper, then treated with standard therapies including hydrogels. Experiment groups were also treated with BPC157 twice a day for 18 days. Wound repair was accelerated substantially with 80% wound closure on day 18, and control group rats showing 60% recovery at the most. Cell migration and endothelial cell production were also markedly improved in the experimental group.
Eye injuries were evaluated in rats for healing potential with BPC157. Anesthetized rats were given a tiny ocular incision under an operating microscope and then treated with BPC157 eye drops every 8 hours for 5 days. BPC157 significantly accelerated the healing process; within 24h fluorescein and Seidel tests were negative. The injuries were completely healed as quickly as 72 hours.
BPC157 was compared to anti-ulcer medications including sucralfate, omeprazole, ranitidine, famotidine, and cimeditine, to evaluate new vessel formation and tissue granulation. Various concentrations of medication were given to rats, and then tissues were biopsied. BPC157 use was shown to actually speed healing via granulation tissue, whereas only sucralfate had been known to do so from this group of study agents; the H2 blockers were no better than placebo.
Rats undergoing evaluation for induced ischemic colitis were given BPC-157 to evaluate recovery. Ischemic colitis can be caused in humans by clotting disorders, and may be fatal or require extensive surgery. The rats that were given BPC157 showed little injury from the procedure compared to control group rats; additionally, they had rapid restoration of blood circulation and tissue recovery. They also showed to have near complete recovery by day 10 of the study, with only tiny lesions present. This showed rapid restoration of blood supply to ischemic areas of the colon via the nitric oxide (NO) system.
Celecoxib was studied in rats and its ability to cause gastrointestinal, liver and brain lesions, as well as its ability to worsen liver function. High-dose celecoxib was administered at 1 g/kg body weight (this is quite high, human doses are typically no more than 400mg a day), followed by evaluation of lesion formation and elevation of LFTs. BPC157 was given as a rescue medication to the rats, and it showed improvement in all the lesions in the BPC157 groups, suspected to be due to nitric oxide (NO) involvement.
The leaky bladder was also studied in rats, with BPC157 as the experimental agent. Female rats with stress urinary incontinence were studied with BPC157 given by injection, or in their water supply. The treated rats underwent testing which showed their function was as normal as healthy rats. Notably, healthy rats had no change in function when treated with BPC157, showing improvement in the group needing treatment, and no side effects in the normal group given BPC157.
Periodontitis, an inflammatory dental condition, was evaluated in rats in a 2009 study. Experiment rats were treated with BPC157 once daily. At the end of 12 days of study, a micro-CAT scan was employed and gingival tissue was harvested and stained for evaluation. BPC157 showed no adverse effects in control rats and showed potent anti-inflammatory effects on periodontal tissues.
Injury-induced sciatica was studied in rats. Surgical transection of rat sciatic nerve was performed, and rats were treated with BPC157. The treated rats showed faster regeneration, increased density, and size of regenerative fibers, and a higher proportion of nerve vs. connective tissue. Functionally, the rats improved as if they had never had the injury.
Mice were studied for their response to BPC157 after a burn by a CO2 laser. The laser was applied to a 0.8mm site with a 1 second exposure time on anesthetized mice. Treatment groups were given BPC157 topical cream. The highest concentration cream showed consistently improved speed and quality of healing following 21 days of treatment. Similar outcomes were shown in heat-induced burns as well.
Portal hypertension and liver lesions have been considered to be diseases which may benefit from BPC157. Portal hypertension is sometimes a consequence of chronic alcohol intake, non-alcoholic steatohepatitis (NASH), and some types of chronic hepatitis including B and C. Rats were given alcohol in drinking water for three months, with simultaneous daily dosing of BPC157. The rats that were treated showed portal venous pressures which were normal, just like control rats. Additional complications of liver disease including fatty or enlarged liver were improved or completely eliminated in the treatment arm of the study.
BPC157 has been shown to have antidepressant activity in rats. Specific structured stress tests were performed, and rats were also given BPC157 to evaluate how they coped when given it. The treated rats showed improved coping response in as little as 4 days.
A 1997 summary analyzed the various actions of BPC157, including blood vessel formation, wound healing, post-surgical intestine healing, granulation tissue formation, and wound tensile strength development. The summary discussed improvement in all of these areas, including the various methods of administration (orally, topically, injected).
All of our products are lab tested and the results are periodically published on the website.
We are negotiating and buying in bulk from top peptide and research chemical manufacturers from around the world to bring the end researcher wholesale discounted prices of the highest quality research chemicals.
1. Molecules. 2014 Nov 19;19(11):19066-77. doi: 10.3390/molecules191119066.
Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Chang CH1, Tsai WC2, Hsu YH3, Pang JH4.
2. Inflammopharmacology. 1999;7(1):1-14. The pharmacological properties of the novel peptide BPC 157 (PL-10). Sikiric P1.
3. Life Sci. 2017 Oct 1;186:66-79. doi: 10.1016/j.lfs.2017.08.006. Epub 2017 Aug 7.
BPC 157 counteracts QTc prolongation induced by haloperidol, fluphenazine, clozapine, olanzapine, quetiapine, sulpiride, and metoclopramide in rats. Strinic D1, Belosic Halle Z1, Luetic K1, Nedic A1, Petrovic I1, Sucic M1, Zivanovic Posilovic G1, Balenovic D1, Strbe S1, Udovicic M1, Drmic D1, Stupnisek M1, Lovric Bencic M1, Seiwerth S1, Sikiric P2.
4. Drug Test Anal. 2017 Oct;9(10):1490-1498. doi: 10.1002/dta.2152. Epub 2017 Feb 10.
Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H.
Cox HD1, Miller GD1,2, Eichner D1,2.
5. Eur J Pharmacol. 2016 Dec 15;793:56-65. doi: 10.1016/j.ejphar.2016.10.035. Epub 2016 Nov 1. Stable gastric pentadecapeptide BPC 157 and bupivacaine.
Zivanovic-Posilovic G1, Balenovic D2, Barisic I3, Strinic D4, Stambolija V5, Udovicic M4, Uzun S5, Drmic D6, Vlainic J7, Bencic ML4, Sindic A8, Seiwerth S9, Sikiric P10.
6. Drug Des Devel Ther. 2015 Apr 30;9:2485-99. doi: 10.2147/DDDT.S82030. eCollection 2015. Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro.
Huang T1, Zhang K2, Sun L3, Xue X1, Zhang C1, Shu Z1, Mu N1, Gu J1, Zhang W1, Wang Y1, Zhang Y1, Zhang W1.
7. Exp Eye Res. 2015 Jul;136:9-15. doi: 10.1016/j.exer.2015.04.016. Epub 2015 Apr 24.
Perforating corneal injury in rat and pentadecapeptide BPC 157. Masnec S1, Kokot A2, Zlatar M3, Kalauz M1, Kunjko K3, Radic B3, Klicek R3, Drmic D3, Lazic R3, Brcic L4, Radic R2, Ivekovic R5, Seiwerth S4, Sikiric P6.
8. J Physiol Paris. 1999 Dec;93(6):479-85. The effect of pentadecapeptide BPC 157, H2-blockers, omeprazole and sucralfate on new vessels and new granulation tissue formation. Sikiric P1, Separovic J, Anic T, Buljat G, Mikus D, Seiwerth S, Grabarevic Z, Stancic-Rokotov D, Pigac B, Hanzevacki M, Marovic A, Rucman R, Petek M, Zoricic I, Ziger T, Aralica G, Konjevoda P, Prkacin I, Gjurasin M, Miklic P, Artukovic B, Tisljar M, Bratulic M, Mise S, Rotkvic I.
9. World J Gastroenterol. 2017 Dec 28;23(48):8465-8488. doi: 0.3748/wjg.v23.i48.8465.
Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: New insights. Duzel A1, Vlainic J1, Antunovic M1, Malekinusic D1, Vrdoljak B1, Samara M1, Gojkovic S1, Krezic I1, Vidovic T1, Bilic Z1, Knezevic M1, Sever M1, Lojo N1, Kokot A1, Kolovrat M1, Drmic D1, Vukojevic J1, Kralj T1, Kasnik K1, Siroglavic M1, Seiwerth S1, Sikiric P2.
10. World J Gastroenterol. 2017 Aug 7;23(29):5304-5312. doi: 0.3748/wjg.v23.i29.5304.
Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME. Drmic D1, Kolenc D1, Ilic S1, Bauk L1, Sever M1, Zenko Sever A1, Luetic K1, Suran J1, Seiwerth S1, Sikiric P1.
11. J Physiol Pharmacol. 2011 Oct;62(5):527-34. BPC 157 therapy to detriment sphincters failure-esophagitis-pancreatitis in rat and acute pancreatitis patients low sphincters pressure. Petrovic I1, Dobric I, Drmic D, Sever M, Klicek R, Radic B, Brcic L, Kolenc D, Zlatar M, Kunjko K, Jurcic D, Martinac M, Rasic Z, Boban Blagaic A, Romic Z, Seiwerth S, Sikiric P.
12. J Physiol Pharmacol. 2009 Dec;60 Suppl 7:115-22. Antiinflammatory effect of BPC 157 on experimental periodontitis in rats. Keremi B1, Lohinai Z, Komora P, Duhaj S, Borsi K, Jobbagy-Ovari G, Kallo K, Szekely AD, Fazekas A, Dobo-Nagy C, Sikiric P, Varga G.
13. Regul Pept. 2010 Feb 25;160(1-3):33-41. doi: 10.1016/j.regpep.2009.11.005. Epub 2009 Nov 10. Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury.
Gjurasin M1, Miklic P, Zupancic B, Perovic D, Zarkovic K, Brcic L, Kolenc D, Radic B, Seiwerth S, Sikiric P.
14. Burns. 2005 May;31(3):310-5. Epub 2005 Jan 20. The stable gastric pentadecapeptide BPC 157, given locally, improves CO2 laser healing in mice. Bilic M1, Bumber Z, Blagaic AB, Batelja L, Seiwerth S, Sikiric P.
15. Burns. 2001 Dec;27(8):817-27. Pentadecapeptide BPC 157 cream improves burn-wound healing and attenuates burn-gastric lesions in mice. Mikus D1, Sikiric P, Seiwerth S, Petricevic A, Aralica G, Druzijancic N, Rucman R, Petek M, Pigac B, Perovic D, Kolombo M, Kokic N, Mikus S, Duplancic B, Fattorini I, Turkovic B, Rotkvic I, Mise S, Prkacin I, Konjevoda P, Stambuk N, Anic T.
16. J Physiol Paris. 2001 Jan-Dec;95(1-6):315-24. Portal hypertension and liver lesions in chronically alcohol drinking rats prevented and reversed by stable gastric pentadecapeptide BPC 157 (PL-10, PLD-116), and propranolol, but not ranitidine.
Prkacin I1, Separovic J, Aralicia G, Perovic D, Gjurasin M, Lovric-Bencic M, Stancic-Rokotov D, Staresinic M, Anic T, Mikus D, Sikiric P, Seiwerth S, Mise S, Rotkvic I, Jagic V, Rucman R, Petek M, Turkovic B, Marovic A, Sebecic B, Boban-Blagaic A, Kokic N.
17. J Physiol Paris. 2000 Mar-Apr;94(2):99-104. The antidepressant effect of an antiulcer pentadecapeptide BPC 157 in Porsolt’s test and chronic unpredictable stress in rats. A comparison with antidepressants. Sikiric P1, Separovic J, Buljat G, Anic T, Stancic-Rokotov D, Mikus D, Marovic A, Prkacin I, Duplancic B, Zoricic I, Aralica G, Lovric-Bencic M, Ziger T, Perovic D, Rotkvic I, Mise S, Hanzevacki M, Hahn V, Seiwerth S, Turkovic B, Grabarevic Z, Petek M, Rucman R.
18. J Physiol Paris. 1997 May-Oct;91(3-5):173-8. BPC 157’s effect on healing.
Seiwerth S1, Sikiric P, Grabarevic Z, Zoricic I, Hanzevacki M, Ljubanovic D, Coric V, Konjevoda P, Petek M, Rucman R, Turkovic B, Perovic D, Mikus D, Jandrijevic S, Medvidovic M, Tadic T, Romac B, Kos J, Peric J, Kolega Z.
Also known as: booly protection compound 15, BPC 15, BPC 157, BPC-15, BPC-157